Cancer prediction using graph-based gene selection and explainable classifier

Several Artificial Intelligence-based models have been developed for cancer prediction. In spite of the promise of artificial intelligence, there are very few models which bridge the gap between traditional human-centered prediction and the potential future of machine-centered cancer prediction. In this study, an efficient and effective model is developed for gene selection and cancer prediction. Moreover, this study proposes an artificial intelligence decision system to provide physicians with a simple and human-interpretable set of rules for cancer prediction. In contrast to previous deep learning-based cancer prediction models, which are difficult to explain to physicians due to their black-box nature, the proposed prediction model is based on a transparent and explainable decision forest model. The performance of the developed approach is compared to three state-of-the-art cancer prediction including TAGA, HPSO and LL. The reported results on five cancer datasets indicate that the developed model can improve the accuracy of cancer prediction and reduce the execution time

Proceedings of the third international molecular pathological epidemiology (MPE) meeting

Molecular pathological epidemiology (MPE) is a transdisciplinary and relatively new scientific discipline that integrates theory, methods and resources from epidemiology, pathology, biostatistics, bioinformatics and computational biology. The underlying objective of MPE research is to better understand the etiology and progression of complex and heterogeneous human diseases with the goal of informing prevention and treatment efforts in population health and clinical medicine. Although MPE research has been commonly applied to investigating breast, lung, and colorectal cancers, its methodology can be used to study most diseases. Recent successes in MPE studies include: 1) the development of new statistical methods to address etiologic heterogeneity; 2) the enhancement of causal inference; 3) the identification of previously unknown exposure-subtype disease associations; and 4) better understanding of the role of lifestyle/behavioral factors on modifying prognosis according to disease subtype. Central challenges to MPE include the relative lack of transdisciplinary experts, educational programs, and forums to discuss issues related to the advancement of the field. To address these challenges, highlight recent successes in the field, and identify new opportunities, a series of MPE meetings have been held at the Dana-Farber Cancer Institute in Boston, MA. Herein, we share the proceedings of the Third International MPE Meeting, held in May 2016 and attended by 150 scientists from 17 countries. Special topics included integration of MPE with immunology and health disparity research. This meeting series will continue to provide an impetus to foster further transdisciplinary integration of divergent scientific fields

Artificial neural networks for diagnosis and survival prediction in colon cancer

ANNs are nonlinear regression computational devices that have been used for over 45 years in classification and survival prediction in several biomedical systems, including colon cancer. Described in this article is the theory behind the three-layer free forward artificial neural networks with backpropagation error, which is widely used in biomedical fields, and a methodological approach to its application for cancer research, as exemplified by colon cancer. Review of the literature shows that applications of these networks have improved the accuracy of colon cancer classification and survival prediction when compared to other statistical or clinicopathological methods. Accuracy, however, must be exercised when designing, using and publishing biomedical results employing machine-learning devices such as ANNs in worldwide literature in order to enhance confidence in the quality and reliability of reported data

Polygenic Risk Score for Cardiovascular Diseases in Artificial Intelligence Paradigm: A Review

Cardiovascular disease (CVD) related mortality and morbidity heavily strain society. The relationship between external risk factors and our genetics have not been well established. It is widely acknowledged that environmental influence and individual behaviours play a significant role in CVD vulnerability, leading to the development of polygenic risk scores (PRS). We employed the PRISMA search method to locate pertinent research and literature to extensively review artificial intelligence (AI)-based PRS models for CVD risk prediction. Furthermore, we analyzed and compared conventional vs. AI-based solutions for PRS. We summarized the recent advances in our understanding of the use of AI-based PRS for risk prediction of CVD. Our study proposes three hypotheses: i) Multiple genetic variations and risk factors can be incorporated into AI-based PRS to improve the accuracy of CVD risk predicting. ii) AI-based PRS for CVD circumvents the drawbacks of conventional PRS calculators by incorporating a larger variety of genetic and non-genetic components, allowing for more precise and individualised risk estimations. iii) Using AI approaches, it is possible to significantly reduce the dimensionality of huge genomic datasets, resulting in more accurate and effective disease risk prediction models. Our study highlighted that the AI-PRS model outperformed traditional PRS calculators in predicting CVD risk. Furthermore, using AI-based methods to calculate PRS may increase the precision of risk predictions for CVD and have significant ramifications for individualized prevention and treatment plans

Polygenic Risk Score for Cardiovascular Diseases in Artificial Intelligence Paradigm

Cardiovascular disease (CVD) related mortality and morbidity heavily strain society. The relationship between external risk factors and our genetics have not been well established. It is widely acknowledged that environmental influence and individual behaviours play a significant role in CVD vulnerability, leading to the development of polygenic risk scores (PRS). We employed the PRISMA search method to locate pertinent research and literature to extensively review artificial intelligence (AI)-based PRS models for CVD risk prediction. Furthermore, we analyzed and compared conventional vs. AI-based solutions for PRS. We summarized the recent advances in our understanding of the use of AI-based PRS for risk prediction of CVD. Our study proposes three hypotheses: i) Multiple genetic variations and risk factors can be incorporated into AI-based PRS to improve the accuracy of CVD risk predicting. ii) AI-based PRS for CVD circumvents the drawbacks of conventional PRS calculators by incorporating a larger variety of genetic and non-genetic components, allowing for more precise and individualised risk estimations. iii) Using AI approaches, it is possible to significantly reduce the dimensionality of huge genomic datasets, resulting in more accurate and effective disease risk prediction models. Our study highlighted that the AI-PRS model outperformed traditional PRS calculators in predicting CVD risk. Furthermore, using AI-based methods to calculate PRS may increase the precision of risk predictions for CVD and have significant ramifications for individualized prevention and treatment plans

A case study of microarray breast cancer classification using machine learning algorithms with grid search cross validation

Breast cancer is one of the leading causes of death and most frequently diagnosed cancer amongst women. Annually, almost half a million women do not survive the disease and die from breast cancer. Machine learning is a subfield of artificial intelligence (AI) and computer science that uses data and algorithms to mimic how humans learn, and gradually improving its accuracy. In this work, simple machine learning methods are used to classify breast cancer microarray data to normal and relapse. The data is from the gene expression omnibus (GEO) website namely GSE45255 and GSE15852. These two datasets are integrated and combined to form a single dataset. The study involved three machine learning algorithms, random forest (RF), extra tree (ET), and support vector machine (SVM). Grid search cross validation (CV) is applied for hyperparameter tuning of the algorithms. The result shows that the tuned SVM is best among the tested algorithms with accuracy of 97.78%. In the future it is recommended to include feature selection method to get the optimal features and better classification accuracies

A case study of microarray breast cancer classification using machine learning algorithms with grid search cross validation

Breast cancer is one of the leading causes of death and most frequently diagnosed cancer amongst women. Annually, almost half a million women do not survive the disease and die from breast cancer. Machine learning is a subfield of artificial intelligence (AI) and computer science that uses data and algorithms to mimic how humans learn, and gradually improving its accuracy. In this work, simple machine learning methods are used to classify breast cancer microarray data to normal and relapse. The data is from the gene expression omnibus (GEO) website namely GSE45255 and GSE15852. These two datasets are integrated and combined to form a single dataset. The study involved three machine learning algorithms, random forest (RF), extra tree (ET), and support vector machine (SVM). Grid search cross validation (CV) is applied for hyperparameter tuning of the algorithms. The result shows that the tuned SVM is best among the tested algorithms with accuracy of 97.78%. In the future it is recommended to include feature selection method to get the optimal features and better classification accuracies

Role of Artificial Intelligence in Radiogenomics for Cancers in the Era of Precision Medicine

Radiogenomics, a combination of “Radiomics” and “Genomics,” using Artificial Intelligence (AI) has recently emerged as the state-of-the-art science in precision medicine, especially in oncology care. Radiogenomics syndicates large-scale quantifiable data extracted from radiological medical images enveloped with personalized genomic phenotypes. It fabricates a prediction model through various AI methods to stratify the risk of patients, monitor therapeutic approaches, and assess clinical outcomes. It has recently shown tremendous achievements in prognosis, treatment planning, survival prediction, heterogeneity analysis, reoccurrence, and progression-free survival for human cancer study. Although AI has shown immense performance in oncology care in various clinical aspects, it has several challenges and limitations. The proposed review provides an overview of radiogenomics with the viewpoints on the role of AI in terms of its promises for computa-tional as well as oncological aspects and offers achievements and opportunities in the era of precision medicine. The review also presents various recommendations to diminish these obstacles